D
David Holmes
Researcher at Novartis
Publications - 5
Citations - 1319
David Holmes is an academic researcher from Novartis. The author has contributed to research in topics: Type 2 diabetes & Insulin. The author has an hindex of 4, co-authored 5 publications receiving 1280 citations.
Papers
More filters
Journal ArticleDOI
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
TL;DR: Improved metabolic control by DPP-4 inhibition in type 2 diabetes is seen in association with reduced glucagon levels and, despite the lower glycemia, unaltered insulin levels.
Journal ArticleDOI
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.
Bo Ahrén,Erik Simonsson,Hillevi Larsson,Mona Landin-Olsson,Hlin Torgeirsson,Per-Anders Jansson,Madeléne Sandqvist,Peter Båvenholm,Suad Efendic,Jan W. Eriksson,Sheila Dickinson,David Holmes +11 more
TL;DR: In inhibition of DPP IV is a feasible approach to the treatment of type 2 diabetes in the early stage of the disease, as concluded in a placebo-controlled double-blind multicenter study.
Journal ArticleDOI
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
Andrea El-Ouaghlidi,Erika Rehring,Jens J. Holst,Anja Schweizer,James E. Foley,David Holmes,Michael A. Nauck +6 more
TL;DR: Sulfonylurea-induced hypoglycemia after the oral administration of glibenclamide is not accentuated by the coadministration of vildagliptin, and may be explained by a negative feedback regulation of GLP-1 and GIP secretion that limits the degree to which the active incretin levels are enhanced.
Journal ArticleDOI
Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
TL;DR: Nateglinide is a safe and effective therapeutic option for treatment of patients with mild to moderate fasting hyperglycemia and elicited a dose-dependent reduction of placebo-adjusted hemoglobin A(1c) and FPG.
Journal ArticleDOI
Comparison of the postprandial glucose and insulin profiles with nateglinide and gliclazide in type 2 diabetic patients
TL;DR: Nateglinide was more effective than gliclazide over an extended postprandial period in type 2 diabetic patients and was associated with earlier, higher and shorter-lived insulin and proinsulin secretory responses.